Cantargia AB and Patheon Biologics B.V. have signed an agreement regarding future production of the antibody CAN04 (nidanilimab). CAN04 is currently in phase IIa clinical development for non-small cell lung cancer and pancreatic cancer. According to the agreement, Cantargia secures additional production capacity for future clinical trials.
 
The antibody CAN04 is currently investigated in a European phase IIa clinical trial for treatment of patients with non-small cell lung cancer or pancreatic cancer. In order to prepare for late stage clinical trials, increased production capacity is part of the development plan. The new supply agreement with Patheon complements the current agreement with Celonic AG (formerly Glycotope Biotechnology GmbH). Patheon will scale up the process to 2000 liters before next production campaign of clinical material. Patheon has manufacturing facilities in both Europe and U.S.
 
“We are very pleased to have added one additional production site to our list of suppliers. This agreement is an important next step in the advancement of our CAN04 clinical program,” said Göran Forsberg, chief executive officer, Cantargia.